26 completed, 20 recruiting, 19 active not recruiting, 18 terminated. 51 Phase 2, 43 Phase 1, 7 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Merkel Cell Carcinoma: new trials by email Literature Review of Merkel Cell Carcinoma trials Research Report on Merkel Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1 ASTX727 + retifanlimab - Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III | Phase 1 / Phase 2 | Not yet recruiting | University of Wisconsin, Madison | 31 | 2026-10-01 | 2026-09-29 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors 225Ac-ETN029, 111In-ETN029 - Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Recruiting | Novartis Pharmaceuticals | 116 | 2025-10-16 | 2026-09-22 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors AZD6750, rilvegostomig - Melanoma, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 120 | 2025-07-29 | 2026-10-08 |
| Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype percutaneous, laparoscopic or laparotomy lesion electrochemotherapy - Primary Visceral Tumors of Any Histotype, Visceral Lesions | Not applicable | Recruiting | Istituto Oncologico Veneto IRCCS | 24 | 2025-07-23 | 2026-04-13 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| Exploring Merkel Cell Carcinoma Clinical Trial Engagement Patterns Merkel Cell Carcinoma | Not yet recruiting | Power Life Sciences Inc. | 500 | 2024-10-01 | 2023-09-15 | |
| Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma Blood Test - Merkel Cell Carcinoma | Not yet recruiting | University Hospital, Montpellier | 25 | 2024-07-01 | 2024-06-13 | |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy Exercise Test - Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma | Not applicable | Active not recruiting | AdventHealth Translational Research Institute | 12 | 2024-06-03 | 2026-03-25 |
| Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination - Merkel Cell Carcinoma | Phase 2 | Recruiting | Melanoma Institute Australia | 20 | 2024-03-11 | 2026-02-17 |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers Eutectic Mixture of Local Anesthetics, Placebo Administration, Questionnaire Administration - Cutaneous Melanoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 100 | 2023-12-19 | 2026-03-10 |
| Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma Biopsy, Biospecimen Collection, Computed Tomography - Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8 | Phase 2 | Active not recruiting | University of Washington | 12 | 2023-11-08 | 2026-08-06 |
| Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) Pembrolizumab, Etoposide, Cisplatin or Carboplatin - Merkel Cell Carcinoma | Phase 2 | Not yet recruiting | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 35 | 2023-11-01 | 2023-10-17 |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NEO212 Oral Capsule, Ipilimumab, Pembrolizumab - Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype | Phase 1 / Phase 2 | Recruiting | Neonc Technologies, Inc. | 134 | 2023-11-01 | 2026-09-24 |
| A Study of CRD3874-SI in People With Solid Tumors CRD3874 - Sarcoma, Merkel Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 81 | 2023-08-25 | 2026-09-21 |
| Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer Pembrolizumab, Lutetium Lu 177 dotatate - Merkel Cell Carcinoma | Phase 2 | Recruiting | Weill Medical College of Cornell University | 18 | 2023-08-03 | 2026-09-25 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer MQ719, Pembrolizumab - Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 56 | 2023-05-04 | 2026-08-12 |
Showing 20 of 96. Sign in to see all of them.
Carcinoma, Merkel Cell (96) · Melanoma (39) · Carcinoma, Renal Cell (19) · Carcinoma, Non-Small-Cell Lung (18) · Uterine Cervical Neoplasms (18) · Small Cell Lung Carcinoma (17) · Carcinoma, Basal Cell (15) · Carcinoma, Hepatocellular (15) · Carcinoma, Transitional Cell (15) · Squamous Cell Carcinoma of Head and Neck (15) · Stomach Neoplasms (15) · Carcinoma, Squamous Cell (13) · Skin Neoplasms (13) · Neoplasm Metastasis (12) · Triple Negative Breast Neoplasms (11)
Adenocarcinoma (96) · DNA Virus Infections (96) · Infections (96) · Neoplasms by Histologic Type (96) · Neoplasms, Germ Cell and Embryonal (96) · Neoplasms, Glandular and Epithelial (96) · Neoplasms, Nerve Tissue (96) · Neuroectodermal Tumors (96) · Polyomavirus Infections (96) · Tumor Virus Infections (96) · Virus Diseases (96) · Carcinoma, Neuroendocrine (95) · Carcinoma (94) · Neuroendocrine Tumors (92) · Neoplasms (87)
pembrolizumab (18) · Nivolumab (13) · avelumab (12) · Ipilimumab (6) · Radiotherapy (6) · atezolizumab (6) · Cyclophosphamide (5) · cemiplimab (5) · Interleukin-2 (4) · durvalumab (4) · fludarabine (4) · ALT-803 (3) · Carboplatin (3) · Cisplatin (3) · Etoposide (3)
H. Lee Moffitt Cancer Center and Research Institute (4) · Memorial Sloan Kettering Cancer Center (4) · ImmunityBio, Inc. (3) · Incyte Corporation (3) · 4SC AG (2) · Dana-Farber Cancer Institute (2) · Fate Therapeutics (2) · M.D. Anderson Cancer Center (2) · Melanoma Institute Australia (2) · National Cancer Institute (NCI) (2) · Philogen S.p.A. (2) · TuHURA Biosciences, Inc. (2) · Abramson Cancer Center at Penn Medicine (1) · AdventHealth Translational Research Institute (1) · Arcus Biosciences, Inc. (1)
United States (67) · Australia (13) · France (12) · Italy (8) · Spain (8) · Canada (6) · United Kingdom (6) · Belgium (5) · Germany (5) · Netherlands (4) · South Korea (4) · Austria (3) · Japan (3) · New Zealand (3) · Sweden (3)
Robert Haddad, MD (2) · Ahmad Tarhini, MD, PhD (1) · Andreas Saltos, MD (1) · Andrew Brohl, MD (1) · Andrew S Brohl, MD (1) · Anna C Pavlick, BSN, MSc, DO, MBA (1) · Arash Yavari, MBBS (1) · Benjamin Thompson, MD, PhD (1) · Bobby Reddy, MD (1) · Bret Goodpaster, PhD (1) · Brian Gastman, MD (1)
PMID 42580817, PMID 21757257, PMID 29445030, PMID 30304652, PMID 31689874, PMID 32819975, PMID 33929874, PMID 35444059, PMID 35507536, PMID 37055772, PMID 37131154, PMID 37451295, PMID 37683276, PMID 37711623, PMID 37848259, PMID 37865395, PMID 39021272, PMID 39377880, PMID 40501309, PMID 41534900, PMID 42402341
2018 (4), 2019 (3), 2023 (2), P30CA015704 (1), UM1CA186709 (1), UM1CA186716 (1)